bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S2 from Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2
Authors: Terashima Masato , Togashi Yosuke , Sato Katsuaki , Mizuuchi Hiroshi , Sakai Kazuko , Suda Kenichi , Nakamura Yu , Banno Eri , Hayashi Hidetoshi , De Velasco Marco A. , Fujita Yoshihiko , Tomida Shuta , Mitsudomi Tetsuya , Nishio Kazuto
Published: April 2023

(A) Protein expression of DDR2 in transfectant PC-9 and H3122 cell lines. The DDR2 mRNA expression level was evaluated using real-time RT-PCR; GAPDH was used as an internal control. The DDR2 protein expression level was evaluated using western blotting. The DDR2 E655K-overexpressed cell lines had particularly low DDR2 protein expressions, compared with the levels in DDR2 WT-overexpressed cell lines, despite having an equal expression of DDR2 mRNA. The DDR2 protein produced a fragmented ladder in the DDR2 E655K-overexpressed cell lines. β-actin was used as an internal control. Columns, mean of independent triplicate experiments; Bars, SD. (B) Cellular proliferation of transfectant PC-9 and H3122 cell lines. Cellular growth was examined using an MTT assay with or without stimulation with collagen I (10 µg/mL). Without collagen I, no significant difference in proliferation was observed among the transfectant cell lines. In contrast, under exposure to collagen I, the cellular proliferations of the DDR2 WT-overexpressed cell lines were significantly reduced, compared with those of the EGFP-overexpressed cell lines, whereas a reduction was not observed in the DDR2 E655K-overexpressed cell lines. Columns, mean of independent triplicate experiments; Bars, SD; *, P < 0.05; n.s., not significant.
Supplementary Figures 1-6 from A Hypoxia-Induced Vascular Endothelial-to-Mesenchymal Transition in Development of Radiation-Induced Pulmonary Fibrosis
Authors: Choi Seo-Hyun , Hong Zhen-Yu , Nam Jae-Kyung , Lee Hae-June , Jang Junho , Yoo Ran Ji , Lee Yong Jin , Lee Chang Young , Kim Kyung Hwan , Park Seungwoo , Ji Young Hoon , Lee Yun-Sil , Cho Jaeho , Lee Yoon-Jin
Published: April 2023

Supplementary Figures 1-6. Supplementary Figure 1. Mouse models of RIPF. Supplementary Figure 2. The ocurrence of EndMT and an EMT in the development of RIPF. Supplementary Figure 3. 2-ME inhibits EMT in the development of RIPF. Supplementary Figure 4. 2-ME inhibits RIPF. Supplementary Figure 5. H&E staining in human RIPF tissues Supplementary Figure 6. Whole-body or thoracic irradiation of mice induces apoptosis and detachment of lung endothelial cells.
Supplemental Tables 1 - 7 from Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity
Authors: Brambilla Christian , Laffaire Julien , Lantuejoul Sylvie , Moro-Sibilot Denis , Mignotte Hélène , Arbib François , Toffart Anne-Claire , Petel Fabien , Hainaut Pierre , Rousseaux Sophie , Khochbin Saadi , de Reyniès Aurélien , Brambilla Elisabeth
Published: April 2023

Supplemental Table 1:A. Characteristics of the antibodies used for immunohistochemical measures B.Clinical characteristics of the CIT cohort of patients. Supplemental Table 2: A .Gene expression related statistics in the CIT cohort. B. immunohistochemistry quickscore measures of SOX4 and IVL and prediction of the basaloid satus Supplemental Table 3: Gene signatures and pathways deregulation analysis in histological subtypes. Supplemental Table 4: DNA copy number aberrations related statistics in the CIT cohort. Supplemental Table 5: 139-gene centroids used for prediction of the CIT molecular subtypes. Supplemental Table 6: Molecular subtype prediction and survival data for each sample of the CIT and 8 validation datasets. Supplemental Table 7: Gene signatures and pathways enrichment analysis in molecular subtypes in the CIT cohort and 4 validation datasets.
Supplemental Tables 1-3, Supplementary Figure Legends from Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer
Authors: Redig Amanda J. , Capelletti Marzia , Dahlberg Suzanne E. , Sholl Lynette M. , Mach Stacy , Fontes Caitlin , Shi Yunling , Chalasani Poornima , Jänne Pasi A.
Published: April 2023

Supplemental Table 1: Identified NF1 variants; Supplemental Table 2: Tumors with multiple NF1 mutations include splice site, missense, nonsense, and frameshift mutations; Supplemental Table 3: KRAS mutations identified by next-generation sequencing.
Sup Figure 2 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
Authors: Yap Timothy A. , Yan Li , Patnaik Amita , Tunariu Nina , Biondo Andrea , Fearen Ivy , Papadopoulos Kyriakos P. , Olmos David , Baird Richard , Delgado Liliana , Tetteh Ernestina , Beckman Robert A. , Lupinacci Lisa , Riisnaes Ruth , Decordova Shaun , Heaton Simon P. , Swales Karen , deSouza Nandita M. , Leach Martin O. , Garrett Michelle D. , Sullivan Daniel M. , de Bono Johann S. , Tolcher Anthony W.
Published: April 2023

Sup Figure 2. Box-and-whisker plots showing that the extent of multiparametric MRI (DCE-MRI (A), DWI (B), 1H-MRS (C) and ISW-MRI (D)) parameter changes in patients on MK-2206
Supplementary Document 2 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Authors: Tramm Trine , Mohammed Hayat , Myhre Simen , Kyndi Marianne , Alsner Jan , Børresen-Dale Anne-Lise , Sørlie Therese , Frigessi Arnoldo , Overgaard Jens
Published: April 2023

Transfer of DBCG-RT profile to RT-qPCR on formalin-fixed, paraffin-embedded material.
Sup Figure 1 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
Authors: Yap Timothy A. , Yan Li , Patnaik Amita , Tunariu Nina , Biondo Andrea , Fearen Ivy , Papadopoulos Kyriakos P. , Olmos David , Baird Richard , Delgado Liliana , Tetteh Ernestina , Beckman Robert A. , Lupinacci Lisa , Riisnaes Ruth , Decordova Shaun , Heaton Simon P. , Swales Karen , deSouza Nandita M. , Leach Martin O. , Garrett Michelle D. , Sullivan Daniel M. , de Bono Johann S. , Tolcher Anthony W.
Published: April 2023

Sup Figure 1. Mean plasma versus time profile for MK-2206 following 60mg QOD dosing for 27 Days in patients on the expansion cohorts
Supplementary Document 1 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Authors: Tramm Trine , Mohammed Hayat , Myhre Simen , Kyndi Marianne , Alsner Jan , Børresen-Dale Anne-Lise , Sørlie Therese , Frigessi Arnoldo , Overgaard Jens
Published: April 2023

Development of the DBCG-RT profile including description of Lasso method, selection of genes, and definition of index cut-off.
Supplemental Video M5 from A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment
Authors: Witney Timothy H. , Hoehne Aileen , Reeves Robert E. , Ilovich Ohad , Namavari Mohammad , Shen Bin , Chin Frederick T. , Rao Jianghong , Gambhir Sanjiv S.
Published: April 2023

Supplemental Video M5. 18FC-SNAT uptake in naive tumors
Supplementary Figure 3 from Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
Authors: Schreibelt Gerty , Bol Kalijn F. , Westdorp Harm , Wimmers Florian , Aarntzen Erik H.J.G. , Duiveman-de Boer Tjitske , van de Rakt Mandy W.M.M. , Scharenborg Nicole M. , de Boer Annemiek J. , Pots Jeanette M. , Olde Nordkamp Michel A.M. , van Oorschot Tom G.M. , Tel Jurjen , Winkels Gregor , Petry Katja , Blokx Willeke A.M. , van Rossum Michelle M. , Welzen Marieke E.B. , Mus Roel D.M. , Croockewit Sandra A.J. , Koornstra Rutger H.T. , Jacobs Joannes F.M. , Kelderman Sander , Blank Christian U. , Gerritsen Winald R. , Punt Cornelis J.A. , Figdor Carl G. , de Vries I. Jolanda M.
Published: April 2023

Supplementary Figure 3. KLH-specific immune responses before and after DC vaccination. (A) KLH-specific T cell proliferation was analyzed before the first vaccination and after each DC vaccination during the first vaccination cycle in peripheral blood of vaccinated metastatic melanoma patients. Per time point each dot represents 1 patient. Proliferative response to KLH is given as proliferation index (proliferation with KLH/proliferation without KLH). The two patients not showing a KLH-specific T cell response are shown in grey. (B) KLH-specific IgG, IgA, and IgM antibodies were quantitatively measured after each vaccination cycle in sera of vaccinated patients. Per isotype each dot represents one patient. Best KLH responses per patient are shown.
Supplementary Figure S5 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
Authors: Kageyama Shinichi , Ikeda Hiroaki , Miyahara Yoshihiro , Imai Naoko , Ishihara Mikiya , Saito Kanako , Sugino Sahoko , Ueda Shugo , Ishikawa Takeshi , Kokura Satoshi , Naota Hiroaki , Ohishi Kohshi , Shiraishi Taizo , Inoue Naoki , Tanabe Masashige , Kidokoro Tomohide , Yoshioka Hirofumi , Tomura Daisuke , Nukaya Ikuei , Mineno Junichi , Takesako Kazutoh , Katayama Naoyuki , Shiku Hiroshi
Published: April 2023

Infiltration of TCR gene-transferred T cells in esophageal tumor sites.
Supplementary Tables 3 and 4 from IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma
Authors: Carson Craig C. , Moschos Stergios J. , Edmiston Sharon N. , Darr David B. , Nikolaishvili-Feinberg Nana , Groben Pamela A. , Zhou Xin , Kuan Pei Fen , Pandey Shaily , Chan Keefe T. , Jordan Jamie L. , Hao Honglin , Frank Jill S. , Hopkinson Dennis A. , Gibbs David C. , Alldredge Virginia D. , Parrish Eloise , Hanna Sara C. , Berkowitz Paula , Rubenstein David S. , Miller C. Ryan , Bear James E. , Ollila David W. , Sharpless Norman E. , Conway Kathleen , Thomas Nancy E.
Published: April 2023

Supplementary Tables 3 and 4. Supplementary Table 3. ITK protein expression levels in cell lines by single fluorescent immunocytochemistry Supplementary Table 4. Statistical analysis of shRNA and BI 10N effects on the proliferation and motility rates of melanoma cell lines
Supplemental Table 2 from Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer
Authors: Yang Ji-Yeon , Werner Henrica M.J. , Li Jie , Westin Shannon N. , Lu Yiling , Halle Mari K. , Trovik Jone , Salvesen Helga B. , Mills Gordon B. , Liang Han
Published: April 2023

Supplemental Table 2. Clinical information and RPPA data on patients in the validation set
Supplementary Figure 2 from IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma
Authors: Carson Craig C. , Moschos Stergios J. , Edmiston Sharon N. , Darr David B. , Nikolaishvili-Feinberg Nana , Groben Pamela A. , Zhou Xin , Kuan Pei Fen , Pandey Shaily , Chan Keefe T. , Jordan Jamie L. , Hao Honglin , Frank Jill S. , Hopkinson Dennis A. , Gibbs David C. , Alldredge Virginia D. , Parrish Eloise , Hanna Sara C. , Berkowitz Paula , Rubenstein David S. , Miller C. Ryan , Bear James E. , Ollila David W. , Sharpless Norman E. , Conway Kathleen , Thomas Nancy E.
Published: April 2023

Supplementary Figure 2. Ingenuity Pathway Analysis Results from RPPA assay and effects of ITK activity on specific cellular proteins by westerns and RPPA results.
Supplementary Table S3 from Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial
Authors: Legat Amandine , Maby-El Hajjami Hélène , Baumgaertner Petra , Cagnon Laurène , Abed Maillard Samia , Geldhof Christine , Iancu Emanuela M. , Lebon Luc , Guillaume Philippe , Dojcinovic Danijel , Michielin Olivier , Romano Emanuela , Berthod Grégoire , Rimoldi Donata , Triebel Frédéric , Luescher Immanuel , Rufer Nathalie , Speiser Daniel E.
Published: April 2023

Maximum frequency of the antigen-specific T-cells identified in the IVS cultures
Supplementary Table S2 from Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial
Authors: Legat Amandine , Maby-El Hajjami Hélène , Baumgaertner Petra , Cagnon Laurène , Abed Maillard Samia , Geldhof Christine , Iancu Emanuela M. , Lebon Luc , Guillaume Philippe , Dojcinovic Danijel , Michielin Olivier , Romano Emanuela , Berthod Grégoire , Rimoldi Donata , Triebel Frédéric , Luescher Immanuel , Rufer Nathalie , Speiser Daniel E.
Published: April 2023

Combinatorial tetramer staining for HLA-A2 restricted CD8 T-cells
Supplementary Methods from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Authors: Cornell Liam , Munck Joanne M. , Alsinet Clara , Villanueva Augusto , Ogle Laura , Willoughby Catherine E. , Televantou Despina , Thomas Huw D. , Jackson Jennifer , Burt Alastair D. , Newell David , Rose John , Manas Derek M. , Shapiro Geoffrey I. , Curtin Nicola J. , Reeves Helen L.
Published: April 2023

Supplementary Methods
Supplementary Figures 1-11 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Authors: Cornell Liam , Munck Joanne M. , Alsinet Clara , Villanueva Augusto , Ogle Laura , Willoughby Catherine E. , Televantou Despina , Thomas Huw D. , Jackson Jennifer , Burt Alastair D. , Newell David , Rose John , Manas Derek M. , Shapiro Geoffrey I. , Curtin Nicola J. , Reeves Helen L.
Published: April 2023

Supplementary Figures 1-11. Supplementary Figure 1. DNA-PK expression and tumour specific PRKDC locus amplification Supplementary Figure 2. DDR gene expression in HCC cells Supplementary Figure 3: DDR protein expression and activity in HCC cells Supplementary Figure 4: Effects of DNA-PKcs knockdown on NHEJ activity Supplementary Figure 5: Clonogenic survival of HCC cells exposed to IR- and doxorubicin-induced cytotoxicity in HCC cells Supplementary Figure 6: DNA-PK inhibition potentiated IR- and doxorubicin-induced cytotoxicity in HCC cells Supplementary Figure 7: ATM inhibition potentiated IR- and doxorubicin-induced cytotoxicity in the majority of HCC cells Supplementary Figure 8: Combination DNA-PK and ATM inhibition suppressed clonogenic survival in the absence of cyctotoxic injury in HCC cells Supplementary Figure 9: Combined ATM and DNA-PK inhibition further potentiated IR and doxorubicin cytotoxicity in HCC cells Supplementary Figure 10: Neither NU7441 nor KU55933 effect nuclear doxorubicin accumulation Supplementary Figure 11: In vivo effects of NU7441 and doxorubicin treatment
Supplemental Figure legends from Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15–CCR1 Chemokine Axis
Authors: Inamoto Susumu , Itatani Yoshiro , Yamamoto Takamasa , Minamiguchi Sachiko , Hirai Hideyo , Iwamoto Masayoshi , Hasegawa Suguru , Taketo Makoto Mark , Sakai Yoshiharu , Kawada Kenji
Published: April 2023

Figure legends of supplemental Figure S1, S2, S3 and S4.
Supplementary Table S1: Transcriptional regulators from Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Authors: Malka-Mahieu Hélène , Newman Michelle , Désaubry Laurent , Robert Caroline , Vagner Stéphan
Published: April 2023

Supplementary Table 1: Transcriptional regulators
Supplementary Figure S3 from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung
Authors: Starmans Maud HW. , Pintilie Melania , Chan-Seng-Yue Michelle , Moon Nathalie C. , Haider Syed , Nguyen Francis , Lau Suzanne K. , Liu Ni , Kasprzyk Arek , Wouters Bradly G. , Der Sandy D. , Shepherd Frances A. , Jurisica Igor , Penn Linda Z. , Tsao Ming-Sound , Lambin Philippe , Boutros Paul C.
Published: April 2023

Supplementary Figure S3. A-F, Contingency tables of predicted RAS pathway activation status vs. reported RAS mutation status in the training data (A,D: Botling dataset) and the validation data (B,E: Bild dataset, C,F: Fouret dataset) considering all genes (n = 19,070) or the selected subset (n = 4,858). G, Permutation study: random gene sets were used to build a Random Forest and classification accuracy was assessed using the OOB error rate (dashed line indicates performance of RAS status classifier).
Supplementary Figure S1 from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung
Authors: Starmans Maud HW. , Pintilie Melania , Chan-Seng-Yue Michelle , Moon Nathalie C. , Haider Syed , Nguyen Francis , Lau Suzanne K. , Liu Ni , Kasprzyk Arek , Wouters Bradly G. , Der Sandy D. , Shepherd Frances A. , Jurisica Igor , Penn Linda Z. , Tsao Ming-Sound , Lambin Philippe , Boutros Paul C.
Published: April 2023

Supplementary Figure S1. Kaplan-Meier survival curve for a cohort of 404 adenocarcinoma patients stratified according to RAS mutation status.
Supplementary Figure S3 from A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis
Authors: Hanniford Doug , Zhong Judy , Koetz Lisa , Gaziel-Sovran Avital , Lackaye Daniel J. , Shang Shulian , Pavlick Anna , Shapiro Richard , Berman Russell , Darvishian Farbod , Shao Yongzhao , Osman Iman , Hernando Eva
Published: April 2023

Supplementary Figure S3. This figure depicts representative micrographs of H&E- and CD45-stained sections of patient tumors indicative of non-brisk and brisk TIL response.
Supplementary Figure S2 from A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis
Authors: Hanniford Doug , Zhong Judy , Koetz Lisa , Gaziel-Sovran Avital , Lackaye Daniel J. , Shang Shulian , Pavlick Anna , Shapiro Richard , Berman Russell , Darvishian Farbod , Shao Yongzhao , Osman Iman , Hernando Eva
Published: April 2023

Supplementary Figure S2. This figure depicts brain metastatsis-free and overall survival, as plotted kaplan-meier survival curves, of high- vs low-risk patients (determined by the miRNA signature + stage model) for patients stratified by stage at diagnosis.
Supplementary Table 1 from Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer
Authors: Patel Hetal , Abduljabbar Rezvan , Lai Chun-Fui , Periyasamy Manikandan , Harrod Alison , Gemma Carolina , Steel Jennifer H. , Patel Naina , Busonero Claudia , Jerjees Dena , Remenyi Judit , Smith Sally , Gomm Jennifer J. , Magnani Luca , Győrffy Balázs , Jones Louise J. , Fuller-Pace Frances , Shousha Sami , Buluwela Laki , Rakha Emad A. , Ellis Ian O. , Coombes R. Charles , Ali Simak
Published: April 2023

Supplementary Table 1. Multivariate Cox Regression Analysis for Time to Distant Metastasis (TTDM)
Supplementary Figures 1-6, Supplementary Tables 1-6 from Dysregulation of c-Myb Pathway by Aberrant Expression of Proto-oncogene MYB Provides the Basis for Malignancy in Adult T-cell Leukemia/lymphoma Cells
Authors: Nakano Kazumi , Uchimaru Kaoru , Utsunomiya Atae , Yamaguchi Kazunari , Watanabe Toshiki
Published: April 2023

Supplementary Figure 1. Influences of MYB-MO-#1 and -#2 on the splicing patterns of MYB mRNAs were tested in Jurkat and TL-Om1; Supplementary Figure 2. The levels of the nine c-Myb target gene products were compared between CD4+ T cells from healthy donors (n = 21) and PBMC from ATL patients (n = 52) in gene expression microarray analyses (GSE33615) conducted in our laboratory; Supplementary Figure 3. The promoter methylation status and the efficiency of c-Myb recruitment; Supplementary Figure 4. In order to explore the biological impacts of c-Myb-9A on cellular physiology, we examined the influence of this isoform on the transactivation of HTLV-1 LTR (long terminal repeat) promoter; Supplementary Figure 5. Activation of NF-ïƒªB by c-Myb proteins (WT-c-Myb,c-Myb-8A, -9A, -9B, -10A, -13A, and -14A) was confirmed by immunocytochemistry for activated p65 in HeLa cells; Supplementary Figure 6. Effects of c-Myb knockdown in Jurkat and TL-Om1. c-Myb knockdown by shRNA (shMyb-#1 or shMyb-#2) against MYB mRNA results in effective downregulations of c-Myb protein (upper panels), total MYB and MYB-9A mRNAs, as well as endogenous c-Myb target gene expression levels (lower graphs) in Jurkat and TL-Om1 cells; Supplementary Table 1. Primer sequences for realtime-PCR.; Supplementary Table 2. Primer sequences for ChIP assays; Supplementary Table 3. Primer sequences for amplification of c-Myb target gene promoters; Supplementary Table 4. Sense and antisense oligos for shRNAs against total MYB mRNA; Supplemetary Table 5. Sequences of MYB-9A mRNA targeting morpholino oligomers; Supplementary Table 6. Clinical information of healthy volunteers and ATL patients enrolled in the present study.
Supplementary Figure 1 from Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Authors: Ikeda Masafumi , Okusaka Takuji , Mitsunaga Shuichi , Ueno Hideki , Tamai Toshiyuki , Suzuki Takuya , Hayato Seiichi , Kadowaki Tadashi , Okita Kiwamu , Kumada Hiromitsu
Published: April 2023

Maximum change from baseline in levels of AFP for individual patients along with their response rate (best of overall tumor response).
Supplementary Tables S1 and S2 from Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
Authors: Hong David S. , Kurzrock Razelle , Wheler Jennifer J. , Naing Aung , Falchook Gerald S. , Fu Siqing , Kim Kevin B. , Davies Michael A. , Nguyen Ly M. , George Goldy C. , Xu Lucy , Shumaker Robert , Ren Min , Mink Jennifer , Bedell Cynthia , Andresen Corina , Sachdev Pallavi , O'Brien James P. , Nemunaitis John
Published: April 2023

Supplementary Tables S1 and S2. Supplementary Table 1. Univariate Cox proportional hazard model analysis using baseline and change in levels of biomarkers with PFS Supplementary Table 2. Multivariate Cox proportional hazard model analysis using baseline and change in levels of biomarkers with PFS
Supplementary Tables S5-7 from Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer
Authors: Yang Yijun , Jia Dingwu , Kim Hogyoung , Abd Elmageed Zakaria Y. , Datta Amrita , Davis Rodney , Srivastav Sudesh , Moroz Krzysztof , Crawford Byron E. , Moparty Krishnarao , Thomas Raju , Hudson Robert S. , Ambs Stefan , Abdel-Mageed Asim B.
Published: April 2023

Table S5. ChIP PCR primer set. Table S6. Patient characteristics of microdissected prostate tumors. Table S7. In silico analysis of hnRNPH1 3'UTR
Supplementary Figure 3 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
Authors: Hobor Sebastijan , Van Emburgh Beth O. , Crowley Emily , Misale Sandra , Di Nicolantonio Federica , Bardelli Alberto
Published: April 2023

PDF file - 38K, Alternative comparative presentation of results presented in Figure 3 C-F.
Supplemental Figure S3 from Nicotine Reduces Survival via Augmentation of Paracrine HGF–MET Signaling in the Pancreatic Cancer Microenvironment
Authors: Delitto Daniel , Zhang Dongyu , Han Song , Black Brian S. , Knowlton Andrea E. , Vlada Adrian C. , Sarosi George A. , Behrns Kevin E. , Thomas Ryan M. , Lu Xiaomin , Liu Chen , George Thomas J. , Hughes Steven J. , Wallet Shannon M. , Trevino Jose G.
Published: April 2023

Nicotine treatment does not lead to c-Met activation in PC cells.
Supplemental Figure S2 from Nicotine Reduces Survival via Augmentation of Paracrine HGF–MET Signaling in the Pancreatic Cancer Microenvironment
Authors: Delitto Daniel , Zhang Dongyu , Han Song , Black Brian S. , Knowlton Andrea E. , Vlada Adrian C. , Sarosi George A. , Behrns Kevin E. , Thomas Ryan M. , Lu Xiaomin , Liu Chen , George Thomas J. , Hughes Steven J. , Wallet Shannon M. , Trevino Jose G.
Published: April 2023

Supplemental Figure S2. Nicotine-mediated induction of c-Met is Src-dependent.
Supplementary Figure S7 from HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Authors: Carson Robbie , Celtikci Basak , Fenning Cathy , Javadi Arman , Crawford Nyree , Perez-Carbonell Lucia , Lawler Mark , Longley Daniel B. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Supplementary Figure S7. MEK1/2 regulates levels of decoy MET in BRAFMT in vitro and in vivo models.
Supplementary Figure S5 from HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Authors: Carson Robbie , Celtikci Basak , Fenning Cathy , Javadi Arman , Crawford Nyree , Perez-Carbonell Lucia , Lawler Mark , Longley Daniel B. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Supplementary Figure S5. Combined c-FLIP and MEK1/2 inhibition results in cell death in BRAFMT CRC models.
Supplementary Figure S1 from HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Authors: Carson Robbie , Celtikci Basak , Fenning Cathy , Javadi Arman , Crawford Nyree , Perez-Carbonell Lucia , Lawler Mark , Longley Daniel B. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Supplementary Figure S1. Sensitivity of BRAFMT and WT CRC cells to MEK1/2 inhibition
Supplemental Figure 2 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
Authors: Katz Steven C. , Burga Rachel A. , McCormack Elise , Wang Li Juan , Mooring Wesley , Point Gary R. , Khare Pranay D. , Thorn Mitchell , Ma Qiangzhong , Stainken Brian F. , Assanah Earle O. , Davies Robin , Espat N. Joseph , Junghans Richard P.
Published: April 2023

Supplemental Figure 2. Flow cytometry gating
Supplementary Figure S2 from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Ma Cynthia X. , Luo Jingqin , Naughton Michael , Ademuyiwa Foluso , Suresh Rama , Griffith Malachi , Griffith Obi L. , Skidmore Zachary L. , Spies Nicholas C. , Ramu Avinash , Trani Lee , Pluard Timothy , Nagaraj Gayathri , Thomas Shana , Guo Zhanfang , Hoog Jeremy , Han Jing , Mardis Elaine , Lockhart Craig , Ellis Matthew J.
Published: April 2023

Supplementary Fig. S2. Mutations in selected genes observed in this trial in contrast to that in COSMIC data
Supplemental Information from Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
Authors: Draper Lindsey M. , Kwong Mei Li M. , Gros Alena , Stevanović Sanja , Tran Eric , Kerkar Sid , Raffeld Mark , Rosenberg Steven A. , Hinrichs Christian S.
Published: April 2023

Table S1 lists human peptide sequences with homology to E6 29-38. Figure S1 shows testing of TCRs raised in HLA-A2 transgenic mice. Figure S2 depicts testing of HPV+ cell lines for HLA-A*02:01-restricted recognition by T cells.
Supplemental Figures S1-6, Tables S1-7 from Impaired Self-Renewal and Increased Colitis and Dysplastic Lesions in Colonic Mucosa of AKR1B8-Deficient Mice
Authors: Shen Yi , Ma Jun , Yan Ruilan , Ling Hongyan , Li Xiaoning , Yang Wancai , Gao John , Huang Chenfei , Bu Yiwen , Cao Yu , He Yingchun , Wan Laxiang , Zu Xuyu , Liu Jianghua , Huang Mei Chris , Stenson William F. , Liao Duan-Fang , Cao Deliang
Published: April 2023

Supplemental Figures S1-6, Tables S1-7. Figure S1. Targeted disruption of AKR1B8 gene. Figure S2. AKR1B and AKR1C subfamily expression. Figure S3. Deficiency of proliferation and self-renewal of colonic crypt cells in AKR1B8 -/- mice. Figure S4. DSS treatment schedules. Figure S5. Spleen size and histological inflammation of AKR1B8 -/- mice treated with 2% DSS. Figure S6. Colitis-associated tumorigenesis in AKR1B8 -/- mice. Supplemental Table S1. Coverage summary of Exome sequencing. Supplemental Table S2. Variations detected throughout the mouse Exome sequencing. Supplemental Table S3. Oncogenes and tumor suppressor genes mutated in AKR1B8 -/- colitis and tumors only, but not in wild type colitis. Supplemental Table S4. Disease Activity Index. Supplemental Table S5. Histopathological Inflammation Score. Supplemental Table S6. Definition of histopathology. Supplemental Table S7. Gene specific primers.
Supplementary Data S1 from Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Authors: Sachs Jeffrey R. , Mayawala Kapil , Gadamsetty Satvik , Kang Soonmo Peter , de Alwis Dinesh P.
Published: April 2023

All data used for quantitative analysis in review, with links to references and additional details
Supplementary methods and Figures S1-S7 from Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model
Authors: Bill Ruben , Fagiani Ernesta , Zumsteg Adrian , Antoniadis Helena , Johansson David , Haefliger Simon , Albrecht Imke , Hilberg Frank , Christofori Gerhard
Published: April 2023

Supplementary methods and Figures S1-S7. Supplementary Methods. Detailed description of reagents and protocols used for immunohistochemical and metastasis analysis, and immunofluorescence microscopy analysis. Supplementary Figure S1. Histopathological staging of insulinoma development in Rip1Tag2 transgenic mice (A); quantification of tumor cell apoptosis (B) and tumor cell proliferation (C) in nintedanib and vehicle-treated Rip1Tag2 mice; determination of the IC50 of nintedanib in repressing cultured insulinoma cells (D). Supplementary Figure S2. Quantification of the number of NG2-positive pericytes (A) and the percentage of perivascular cells not associated with blood vessels (B) in tumors of nintedanib and vehicle-treated Rip1Tag2 mice. Supplementary Figure S3. Quantification and localization of hypoxic areas in tumors of nintedanib and vehicle-treated Rip1Tag2 mice (A-D). Supplementary Figure S4. Quantification of microvessel density (A), tumor volumes (B) and tumor grading (C) in tumors of nintedanib, PTK/ZK, sunitinib and vehicle-treated Rip1Tag2 mice. Supplementary Figure S5. Quantification of liver metastasis in mice treated open-end with nintedanib. Supplementary Figure S6. Quantification of microvessel density (A, C) and tumor volumes (B, D) of tumors from Rip1Tag2 mice treated for 5 days with nintedanib (A, B) or for 3 weeks with sunitinib (C, D). Supplementary Figure S7. Quantification of microvessel density (A, C) and volumes (B, D) of tumors from Rip1Tag2 mice treated with PTK/ZK following the onset of tumorigenesis for 3, 4, 5, and 6 weeks (A, B) or for 5 days at a later stage of tumor development (C, D).
Supplemental table 2 from Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Authors: Ingold Heppner Barbara , Untch Michael , Denkert Carsten , Pfitzner Berit M. , Lederer Bianca , Schmitt Wolfgang , Eidtmann Holger , Fasching Peter A. , Tesch Hans , Solbach Christine , Rezai Mahdi , Zahm Dirk M. , Holms Frank , Glados Manfred , Krabisch Petra , Heck Esther , Ober Angelika , Lorenz Petra , Diebold Kurt , Habeck Jörg-Olaf , Loibl Sibylle
Published: April 2023

Correlation of TILs and clinicopathological parameters
Supplemental table 1 from Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Authors: Ingold Heppner Barbara , Untch Michael , Denkert Carsten , Pfitzner Berit M. , Lederer Bianca , Schmitt Wolfgang , Eidtmann Holger , Fasching Peter A. , Tesch Hans , Solbach Christine , Rezai Mahdi , Zahm Dirk M. , Holms Frank , Glados Manfred , Krabisch Petra , Heck Esther , Ober Angelika , Lorenz Petra , Diebold Kurt , Habeck Jörg-Olaf , Loibl Sibylle
Published: April 2023

Baseline characteristics
Supplementary Table 2 from Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer
Authors: Liu Stephen V. , Tsao-Wei Denice D. , Xiong Shigang , Groshen Susan , Dorff Tanya B. , Quinn David I. , Tai Yu-Chong , Engel Juergen , Hawes Debra , Schally Andrew V. , Pinski Jacek K.
Published: April 2023

Supplemental Table 2. Grade 1, 2, 3 and 4 adverse events including all cohorts (n=18). Toxicities defined as not related to treatment were excluded.
Supplemental Figure 3.2 from iNOS Expression in CD4+ T Cells Limits Treg Induction by Repressing TGFβ1: Combined iNOS Inhibition and Treg Depletion Unmask Endogenous Antitumor Immunity
Authors: Jayaraman Padmini , Alfarano Matthew G. , Svider Peter F. , Parikh Falguni , Lu Geming , Kidwai Sarah , Xiong Huabao , Sikora Andrew G.
Published: April 2023

Supplemental Figure 3.2. Splenocytes ( CFSE labelled) from naÃƒÂ¯ve WT mice were activated with soluble anti-CD3 and anti-CD28 antibodies in the presence of RFP+Treg cells sorted (as mentioned above) from control, LNIL and TGF-ÃŽÂ² groups. After 72 hours, cells were havested and surface stained for CD8 T cells and CFSE dilution profile was measured by flow cytometry.
Supplementary Figure 6 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

HDACI-specific effects on c-Myc acetylation.
Supplemental Figure 2 from iNOS Expression in CD4+ T Cells Limits Treg Induction by Repressing TGFβ1: Combined iNOS Inhibition and Treg Depletion Unmask Endogenous Antitumor Immunity
Authors: Jayaraman Padmini , Alfarano Matthew G. , Svider Peter F. , Parikh Falguni , Lu Geming , Kidwai Sarah , Xiong Huabao , Sikora Andrew G.
Published: April 2023

Supplemental Figure 2. Splenocytes from FOXP3 reporter mice were activated with soluble anti-CD3 and anti-CD28 antibodies in the presence or absence of L-NIL or TGF-ÃŽÂ²1 or alone for 5 days after which RFP+ cells were sorted from all the groups and used for T-reg suppression assay with CFSE labelled naÃƒÂ¯ve CD4 T cells.
Supplementary Figure legends from Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma
Authors: Otsuka Atsushi , Dreier Jil , Cheng Phil F. , Nägeli Mirjam , Lehmann Holger , Felderer Lea , Frew Ian J. , Matsushita Shigeto , Levesque Mitchell P. , Dummer Reinhard
Published: April 2023

Legends for S1 and S2
Supplementary Figure 2 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer
Authors: Nebbioso Angela , Carafa Vincenzo , Conte Mariarosaria , Tambaro Francesco Paolo , Abbondanza Ciro , Martens Joost , Nees Matthias , Benedetti Rosaria , Pallavicini Isabella , Minucci Saverio , Garcia-Manero Guillermo , Iovino Francesco , Lania Gabriella , Ingenito Concetta , Belsito Petrizzi Valeria , Stunnenberg Hendrik G. , Altucci Lucia
Published: April 2023

Effects of c-Myc overexpression, p21shRNA and TRAILshRNA (A).
Supplementary table 1 from Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Authors: Tang Ke-Jing , Constanzo Jerfiz D. , Venkateswaran Niranjan , Melegari Margherita , Ilcheva Mariya , Morales Julio C. , Skoulidis Ferdinandos , Heymach John V. , Boothman David A. , Scaglioni Pier Paolo
Published: April 2023

Supplementary Table 1. The table shows the mutations reported by the COSMIC database for every cell line used in our study.
Supplementary figure 5 from Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Authors: Tang Ke-Jing , Constanzo Jerfiz D. , Venkateswaran Niranjan , Melegari Margherita , Ilcheva Mariya , Morales Julio C. , Skoulidis Ferdinandos , Heymach John V. , Boothman David A. , Scaglioni Pier Paolo
Published: April 2023

Supplementary Figure 5. Ionizing radiations and FAK blockade increase the number and persistence of DNA damage foci.
Supplementary Figure 5 from Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation
Authors: Hung Amos C. , Lo Steven , Hou Ming-Feng , Lee Yi-Chen , Tsai Chun-Hao , Chen Yuan-Yin , Liu Wangta , Su Yu-Han , Lo Yi-Hsuan , Wang Chie-Hong , Wu Shiou-Chen , Hsieh Ya-Ching , Hu Stephen Chu-Sung , Tai Ming-Hong , Wang Yun-Ming , Yuan Shyng-Shiou F.
Published: April 2023

Supplementary Figure 5. Body weight and blood test for orthotopic xenograft nude mice.
Supplementary figure 4 from Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Authors: Tang Ke-Jing , Constanzo Jerfiz D. , Venkateswaran Niranjan , Melegari Margherita , Ilcheva Mariya , Morales Julio C. , Skoulidis Ferdinandos , Heymach John V. , Boothman David A. , Scaglioni Pier Paolo
Published: April 2023

Supplementary Figure 4. Radiosensitization induced by FAK blockade is accompanied by persistence of DNA damage foci.
Supplementary Figure 3 from Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation
Authors: Hung Amos C. , Lo Steven , Hou Ming-Feng , Lee Yi-Chen , Tsai Chun-Hao , Chen Yuan-Yin , Liu Wangta , Su Yu-Han , Lo Yi-Hsuan , Wang Chie-Hong , Wu Shiou-Chen , Hsieh Ya-Ching , Hu Stephen Chu-Sung , Tai Ming-Hong , Wang Yun-Ming , Yuan Shyng-Shiou F.
Published: April 2023

Supplementary Figure 3. A-B, Effect of visfatin on cell viability and activation of c-Abl and STAT3 in SKBR-3 breast cancer cells.
Supplementary Figure 2 from Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation
Authors: Hung Amos C. , Lo Steven , Hou Ming-Feng , Lee Yi-Chen , Tsai Chun-Hao , Chen Yuan-Yin , Liu Wangta , Su Yu-Han , Lo Yi-Hsuan , Wang Chie-Hong , Wu Shiou-Chen , Hsieh Ya-Ching , Hu Stephen Chu-Sung , Tai Ming-Hong , Wang Yun-Ming , Yuan Shyng-Shiou F.
Published: April 2023

Supplementary Figure 2. Association of disease-free survival with serum visfatin levels according to adjuvant treatment in breast cancer patients.
Supplementary figure 1 from Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Authors: Tang Ke-Jing , Constanzo Jerfiz D. , Venkateswaran Niranjan , Melegari Margherita , Ilcheva Mariya , Morales Julio C. , Skoulidis Ferdinandos , Heymach John V. , Boothman David A. , Scaglioni Pier Paolo
Published: April 2023

Supplementary Figure 1. Suppression of FAK leads to loss of viability in mutant KRAS NSCLC cells.
Supplementary Figure 1 from Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation
Authors: Hung Amos C. , Lo Steven , Hou Ming-Feng , Lee Yi-Chen , Tsai Chun-Hao , Chen Yuan-Yin , Liu Wangta , Su Yu-Han , Lo Yi-Hsuan , Wang Chie-Hong , Wu Shiou-Chen , Hsieh Ya-Ching , Hu Stephen Chu-Sung , Tai Ming-Hong , Wang Yun-Ming , Yuan Shyng-Shiou F.
Published: April 2023

Supplementary Figure 1. Association of overall survival with serum visfatin levels according to adjuvant treatment in breast cancer patients.
Supplemental Methods and Supplemental Figures 1-9 from Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas
Authors: Margol Ashley S. , Robison Nathan J. , Gnanachandran Janahan , Hung Long T. , Kennedy Rebekah J. , Vali Marzieh , Dhall Girish , Finlay Jonathan L. , Erdreich-Epstein Anat , Krieger Mark D. , Drissi Rachid , Fouladi Maryam , Gilles Floyd H. , Judkins Alexander R. , Sposto Richard , Asgharzadeh Shahab
Published: April 2023

Supplemental Methods and Supplemental Figures 1-9 Supplemental Figure 1. Overview of samples studies and 31-gene signature development Supplemental Figure. 2. Non-negative matrix factorization (NMF) analysis of the combined cohort of medulloblastoma samples (n=168) (A) Cophenetic correlation coefficient based on 2000 clustering runs for 2-10 clusters utilizing genes obtained at varying coefficients of variation; the data demonstrate that the highest cophenetic correlation coefficient was obtained at 4 clusters with 369 genes. (B) NMF consensus heatmap of 4 subgroups using the dataset containing 369 genes with high coefficient of variation. (C) Silhouette plot for identification of outliers. Outliers (n=31) were defined as samples with a silhouette width <0.15. Supplemental Figure 3. HuEx expression levels of CSF1R are significantly higher in SHH tumors compared to Group 3 or Group 4 subgroups (p<0.0001 respectively). Supplemental Figure 4. Progression free survival (PFS) and overall survival (OS) analyses using Kaplan-Meier plots and log rank tests for samples analyzed using TLDA 31-gene signature (A) PFS by molecular subgroup. (B) OS by molecular subgroup. Supplemental Figure 5. TLDA expression levels of CD163 are similar among histologic subtypes of SHH medulloblastomas Supplemental Figure 6. Progression free survival (PFS) and overall survival (OS) analyses using Kaplan-Meier plots and log rank tests for SHH tumors based on median TLDA expression of CD163.(A) PFS of high- vs low-expressers. (B) OS of high- vs low-expressers. Children who died of treatment-related toxicity without evidence of disease progression are excluded from the analyses (n=3). Supplemental Figure 8. Representative IHC images of SHH tumors with desmoplastic histology stained with anti-Ki-67 antibody demonstrating increased cell proliferation in internodular areas corresponding to the presence of macrophages. Supplemental Figure 7. Additional representative (2 per group) of CD163 IHC images of SHH with desmoplastic histology, SHH with classic histology, Group 3 and Group 4 tumors. Supplemental Figure 8. Representative IHC images of SHH tumors with desmoplastic histology stained with anti-Ki-67 antibody demonstrating increased cell proliferation in internodular areas corresponding to the presence of macrophages. Supplemental Figure 9. Unsupervised clustering of the 40 most variable macrophage related genes. Heatmap demonstrating clustering of SHH and WNT group of tumors compared to Group 3/4 tumors. Rows represent names of genes and HuEx probeset identification. White to red coloring indicates expression level of the gene (log2).
Table S1 from SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Authors: Hidalgo Manuel , Plaza Carlos , Musteanu Monica , Illei Peter , Brachmann Carrie B. , Heise Carla , Pierce Daniel , Lopez-Casas Pedro P. , Menendez Camino , Tabernero Josep , Romano Alfredo , Wei Xinyu , Lopez-Rios Fernando , Von Hoff Daniel D.
Published: April 2023

Table S1. Baseline Characteristics in the Stromal SPARC-Evaluable Population
Supplementary Figure 2 from Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma
Authors: Kephart Julie J.G. , Tiller Rosanne G.J. , Crose Lisa E.S. , Slemmons Katherine K. , Chen Po-Han , Hinson Ashley R. , Bentley Rex C. , Chi Jen-Tsan Ashley , Linardic Corinne M.
Published: April 2023

Supplementary Figure 2. SFRP3 suppression increases apoptosis in Rh30 cells.
Supplementary Figure 9-10 GSEA and MCM from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang G. , Kothari Vishal , Santola Alyssa , Liu Meilan , Wilder-Romans Kari , Evans Joseph , Batra Nidhi , Bartelink Harry , Hayes Daniel F. , Lawrence Theodore S. , Brown Powel H. , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Sup. Fig. 9 depicts GSEA analysis nominating DNA repair as a mechanism, Sup. Fig. 10 depicts molecular concept mapping (MCM) of MELK regulated genes
Supp Figure 2-5 MELK RNA and protein expression and clonogenic survival from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang G. , Kothari Vishal , Santola Alyssa , Liu Meilan , Wilder-Romans Kari , Evans Joseph , Batra Nidhi , Bartelink Harry , Hayes Daniel F. , Lawrence Theodore S. , Brown Powel H. , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Figure 2A-C depict MELK RNA expression levels in breast cancer cell lines, Sup. Fig. 3 depicts MELK protein expression levels and correlation between MELK protein and RNA expression, Sup. Fig. 4 depicts SF2Gy and toxicity data for the cell lines. Sup. Fig. 5 depicts clonogenic survival data for shMELK and MELK inhibitor treatment
supplementary figures from SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway
Authors: Chini Claudia C.S. , Espindola-Netto Jair M. , Mondal Gourish , Guerrico Anatilde M. Gonzalez , Nin Veronica , Escande Carlos , Sola-Penna Mauro , Zhang Jin-San , Billadeau Daniel D. , Chini Eduardo N.
Published: April 2023

supplementary figures S1-15. S1- STAC's inhibition of pancreatic cell viability is greater in low serum conditions. S2-SRT1460 inhibits growth and colony formation of Patu8988t cells. S3-STACs sensitize pancreatic cancer cells to Paclitaxel and Gemcitabine. S4- Weight of mice during treatment with SRT1720 in vivo. S5- STACs do not disrupt lysosomes. S6- Lysosomal inhibitors decrease LysoTracker Red labeling. S7- SRT1460 and SRT3025 increase LC3-II and p62 levels. S8- Lysosomal inhibitors increase LC3-II and p62 levels. S9- Different concentrations of SRT1720 induce cleavage of PARP-1 and Caspase-3. S10- Addition of SRT1720 and bafilomycin A1 increase levels of LC3-II and p62. S11-Combination of SRT1720 with chloroquine and ammnonium chloride increase expression of LC3 and decreases cleavage of caspase-3. S12- Activation of SIRT1 by SRT1720 in the presence of DBC1. S13- Quantitative PCR analysis of SIRT1 and DBC1 mRNA expression in pancreatic cell lines. S14- SIRT1 regulates the effect of SRT1460 on cell viability. S15- Quantitative PCR analysis of SIRT1 and DBC1 mRNA expression in matched human pancreatic tumor and adjacent non-tumor pancreas.
Supplementary Figures S1 - S2 from Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle
Authors: Dreaden Erik C. , Kong Yi Wen , Morton Stephen W. , Correa Santiago , Choi Ki Young , Shopsowitz Kevin E. , Renggli Kasper , Drapkin Ronny , Yaffe Michael B. , Hammond Paula T.
Published: April 2023

Fig. S1. Drug-interaction matrix plotting cell killing observed in excess of the additive Bliss expectation between MEK and PI3K inhibition in Pt-resistant epithelial ovarian carcinoma (OVCAR3; 0.20-100 microM, 48 h).Ï‘ Fig. S2. Changes in serum cytokine levels following a single i.v. bolus of LbL nanoparticles in immuno-competent BALC/c mice at t=0 h. Error represents SD of 4 technical replicates from n=3 mice.